{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:39:32Z","timestamp":1787017172626,"version":"build-2736575974"},"reference-count":59,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Due to the multisystemic nature of sickle cell disease (SCD), complications can occur together and thus discerning costs associated with individual complications requires a methodology that can estimate the costs of a given complication while accounting for the presence of other complications. In this study, we aimed to estimate period-based incremental costs associated with specific chronic complications in patients with SCD in England while accounting for multimorbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design\/setting<\/jats:title>\n                    <jats:p>All-cause primary and secondary care healthcare resource utilisation (HCRU) was obtained for a retrospective cohort of patients with SCD using Clinical Practice Research Datalink (CPRD) Aurum linked to Hospital Episode Statistics (HES) datasets. Annualised HCRU and costs were calculated, dividing patient-level events by patient-level time (in years) to obtain per person per year estimates. A series of generalised linear models were used with adjustment for demographic factors and proportion of follow-up time with each complication to estimate the costs associated with 10 chronic SCD-related complications of interest. For these costs, annual equivalent costs can be obtained by dividing by the median follow-up time of 4.74 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with a diagnosis of SCD, with or without complications, in CPRD or HES with at least 12 months follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Period-based all-cause direct healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 1271 patients with SCD included in the study, 49.9% (n=634) had at least one complication and of these 41.3% (n=262) had two or more complications either at baseline or during follow-up. Patients with complications had higher all-cause healthcare costs compared with patients without complications (mean (SD) annualised cost \u00a316 058 (\u00a321 488) vs \u00a34399 (\u00a36635)). Patients with complications had four times the number of annualised inpatient admissions (6.1 vs 1.5 admissions) and more than double the number of annualised bed days in hospital (8.3 vs 3.8\u2009days) over a median 4.74 years of follow-up. Of the complications evaluated, end-stage renal disease had the highest estimated incremental cost of \u00a3252 083 (95% CI \u00a3214 478 to \u00a3283 745) over 4.74 years; this is in addition to the \u00a318 547 period-based cost among patients with SCD without complications. Osteonecrosis was the most common complication with an estimated incremental cost of \u00a327 399 (95% CI \u00a36417 to \u00a343 319) over the same period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Estimating the cost of complications, while accounting for multimorbidity, is essential to determine the true direct cost of SCD. The modelling method presented in our study provides period-based estimates of cost and hospital admissions for individual complications in patients with SCD, accounting for multimorbidity. This approach can be used and extended to other diseases with multisystemic complications to estimate the direct HCRU and costs of individual complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106082","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:41:43Z","timestamp":1770219703000},"page":"e106082","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Direct healthcare costs associated with sickle cell disease complications: a retrospective cohort study using routinely collected healthcare data in England"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1756-1190","authenticated-orcid":false,"given":"Giovanna Tedesco","family":"Barcelos","sequence":"first","affiliation":[{"name":"Pfizer AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Besser","sequence":"additional","affiliation":[{"name":"Department of Haematology, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Davidson","sequence":"additional","affiliation":[{"name":"Specialty EMR Data Division, CorEvitas, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Filonenko","sequence":"additional","affiliation":[{"name":"Pfizer, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Telfer","sequence":"additional","affiliation":[{"name":"Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Joao Carvalho","sequence":"additional","affiliation":[{"name":"Specialty EMR Data Division, CorEvitas, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Wirz","sequence":"additional","affiliation":[{"name":"Pfizer AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3017-2279","authenticated-orcid":false,"given":"Caoimhe T","family":"Rice","sequence":"additional","affiliation":[{"name":"Specialty EMR Data Division, CorEvitas, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026062610402430000_16.2.e106082.1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdx172"},{"key":"2026062610402430000_16.2.e106082.2","unstructured":"NHS England . Sickle cell and thalassaemia screening: data report 2019 to 2020. 2022. Available: https:\/\/www.gov.uk\/government\/publications\/sickle-cell-and-thalassaemia-screening-data-report-2019-to-2020\/sickle-cell-and-thalassaemia-screening-data-report-2019-to-2020 [Accessed 28 Jun 2024]."},{"key":"2026062610402430000_16.2.e106082.3","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026062610402430000_16.2.e106082.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7424.1151"},{"key":"2026062610402430000_16.2.e106082.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.09.001"},{"key":"2026062610402430000_16.2.e106082.6","first-page":"1121","article-title":"The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study","volume":"26","author":"Campbell","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2026062610402430000_16.2.e106082.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05500.x"},{"key":"2026062610402430000_16.2.e106082.8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21905"},{"key":"2026062610402430000_16.2.e106082.9","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-3-50","article-title":"Health related quality of life in sickle cell patients: the PiSCES project","volume":"3","author":"McClish","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"2026062610402430000_16.2.e106082.10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s41669-022-00330-w","article-title":"Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis","volume":"6","author":"Baldwin","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"2026062610402430000_16.2.e106082.11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26063"},{"key":"2026062610402430000_16.2.e106082.12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ajh.25202","article-title":"Clustering of end\u2010organ disease and earlier mortality in adults with sickle cell disease: A retrospective\u2010prospective cohort study","volume":"93","author":"Chaturvedi","year":"2018","journal-title":"American J Hematol"},{"key":"2026062610402430000_16.2.e106082.13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ccl.2010.04.004","article-title":"The effects of heart failure on renal function","volume":"28","author":"Udani","year":"2010","journal-title":"Cardiol Clin"},{"key":"2026062610402430000_16.2.e106082.14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006281"},{"key":"2026062610402430000_16.2.e106082.15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21408"},{"key":"2026062610402430000_16.2.e106082.16","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/bloodadvances.2023012477","article-title":"Costs and impact of disease in adults with sickle cell disease: a pilot study","volume":"8","author":"Lanzkron","year":"2024","journal-title":"Blood Adv"},{"key":"2026062610402430000_16.2.e106082.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253986","article-title":"Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database","volume":"16","author":"Leleu","year":"2021","journal-title":"PLoS One"},{"key":"2026062610402430000_16.2.e106082.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-019-1225-7","article-title":"Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study","volume":"17","author":"Shah","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"2026062610402430000_16.2.e106082.19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21049"},{"key":"2026062610402430000_16.2.e106082.20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3111\/13696998.2015.1117979","article-title":"Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia","volume":"19","author":"Vekeman","year":"2016","journal-title":"J Med Econ"},{"key":"2026062610402430000_16.2.e106082.21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0333"},{"key":"2026062610402430000_16.2.e106082.22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21058"},{"key":"2026062610402430000_16.2.e106082.23","unstructured":"Sickle Cell Society . Standards for the clinical care of adults with sickle cell disease in the UK. 2018. Available: https:\/\/www.stgeorges.nhs.uk\/wp-content\/uploads\/2020\/02\/SCS-Standards-for-the-Care-of-Adults-with-SCD-2018.pdf [Accessed 28 Aug 2025]."},{"key":"2026062610402430000_16.2.e106082.24","doi-asserted-by":"crossref","unstructured":"Grosse SD , Green NS , Reeves SL . Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research. Pediatric Blood Cancer 2020;67. doi:10.1002\/pbc.28703","DOI":"10.1002\/pbc.28703"},{"key":"2026062610402430000_16.2.e106082.25","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5769","article-title":"Standardization of coding definitions for sickle cell disease complications: A systematic literature review","volume":"33","author":"Ericksen","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026062610402430000_16.2.e106082.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278137","article-title":"Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study","volume":"17","author":"Ramsey","year":"2022","journal-title":"PLoS One"},{"key":"2026062610402430000_16.2.e106082.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1765","article-title":"Management of sickle cell disease in the community","volume":"348","author":"Brousse","year":"2014","journal-title":"BMJ"},{"key":"2026062610402430000_16.2.e106082.28","unstructured":"Curtis LA , Burns A . Unit costs of health and social care 2019. Available: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2019\/ [Accessed 23 Apr 2024]."},{"key":"2026062610402430000_16.2.e106082.29","unstructured":"NHS England . Past national tariff: documents and policies 2022\/23. 2023. Available: https:\/\/www.england.nhs.uk\/publication\/past-national-tariffs-documents-and-policies [Accessed Oct 2024]."},{"key":"2026062610402430000_16.2.e106082.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00620-6"},{"key":"2026062610402430000_16.2.e106082.31","unstructured":"Jones K , Weatherly H , Birch S , et al . Unit costs of health and social care 2022 manual. 2023. Available: https:\/\/kar.kent.ac.uk\/100519\/"},{"key":"2026062610402430000_16.2.e106082.32","unstructured":"NHS England . In centre haemodialysis (ICHD): main and satellite units. 2018. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/08\/In-centre-haemodialysis.pdf [Accessed 14 Apr 2025]."},{"key":"2026062610402430000_16.2.e106082.33","unstructured":"NHS England . 2018\/19 national cost collection data publication. 2022. Available: https:\/\/www.england.nhs.uk\/publication\/2018-19-national-cost-collection-data-publication\/ [Accessed 27 Nov 2024]."},{"key":"2026062610402430000_16.2.e106082.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-015-0054-0","article-title":"What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?","volume":"16","author":"Kent","year":"2015","journal-title":"BMC Nephrol"},{"key":"2026062610402430000_16.2.e106082.35","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzr010"},{"key":"2026062610402430000_16.2.e106082.36","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1099"},{"key":"2026062610402430000_16.2.e106082.37","unstructured":"Jones AM . Models for health care. 2010. Available: https:\/\/www.york.ac.uk\/media\/economics\/documents\/herc\/wp\/10_01.pdf [Accessed 27 Jun 2024]."},{"key":"2026062610402430000_16.2.e106082.38","unstructured":"McLennan D , Noble S , Wright G , et al . The English indices of deprivation 2019 technical report. 2019. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/833951\/IoD2019_Technical_Report.pdf [Accessed 27 Jun 2024]."},{"key":"2026062610402430000_16.2.e106082.39","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/1.3.299"},{"key":"2026062610402430000_16.2.e106082.40","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1556"},{"key":"2026062610402430000_16.2.e106082.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02427-9","article-title":"Costs of multimorbidity: a systematic review and meta-analyses","volume":"20","author":"Tran","year":"2022","journal-title":"BMC Med"},{"key":"2026062610402430000_16.2.e106082.42","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/jha2.575","article-title":"Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis","volume":"3","author":"Manwani","year":"2022","journal-title":"EJHaem"},{"key":"2026062610402430000_16.2.e106082.43","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/13696998.2022.2133824","article-title":"Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis","volume":"25","author":"Gallagher","year":"2022","journal-title":"J Med Econ"},{"key":"2026062610402430000_16.2.e106082.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297469","article-title":"Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications","volume":"19","author":"Singh","year":"2024","journal-title":"PLoS ONE"},{"key":"2026062610402430000_16.2.e106082.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269703","article-title":"Economic burden of sickle cell disease in Brazil","volume":"17","author":"Silva-Pinto","year":"2022","journal-title":"PLoS One"},{"key":"2026062610402430000_16.2.e106082.46","unstructured":"Lee S , Vania DK , Bhor M , et al . Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review"},{"key":"2026062610402430000_16.2.e106082.47","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/ckj\/sfac168","article-title":"Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort","volume":"15","author":"Pollock","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026062610402430000_16.2.e106082.48","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afz162"},{"key":"2026062610402430000_16.2.e106082.49","doi-asserted-by":"crossref","first-page":"1753466621995040","DOI":"10.1177\/1753466621995040","article-title":"Burden of pulmonary arterial hypertension in England: retrospective HES database analysis","volume":"15","author":"Exposto","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"2026062610402430000_16.2.e106082.50","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026062610402430000_16.2.e106082.51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/2396987317746516","article-title":"The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke","volume":"3","author":"Xu","year":"2018","journal-title":"Eur Stroke J"},{"key":"2026062610402430000_16.2.e106082.52","unstructured":"NHS England . Clinical commissioning policy: treatment of iron overload for transfused and non-transfused patients with chronic inherited anaemias (all ages). 2022. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2022\/10\/2109-Clinical-commissioning-policy-treatment-of-iron-overload-for-transfused-and-non-transfused-patients-with-.pdf [Accessed 28 Aug 2025]."},{"key":"2026062610402430000_16.2.e106082.53","unstructured":"NHS England . Iron chelation therapy in transfused and non-transfused patients with chronic anaemias: thalassaemia and sickle-cell disease. 2014. Available: https:\/\/www.engage.england.nhs.uk\/consultation\/clinical-commissioning-wave13\/user_uploads\/ff05x02-iron-chelation-thrpy-evidnc-rev.pdf#:~:text=%EF%82%B7%20The%20estimated%20annual%20costs%20of%20the%20three,We%20did%20not%20identify%20any%20specific%20equity%20issues [Accessed 28 Aug 2025]."},{"key":"2026062610402430000_16.2.e106082.54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08150.x"},{"key":"2026062610402430000_16.2.e106082.55","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/trf.15982","article-title":"Automated exchange compared to manual and simple blood transfusion attenuates rise in ferritin level after 1 year of regular blood transfusion therapy in chronically transfused children with sickle cell disease","volume":"60","author":"Kelly","year":"2020","journal-title":"Transfusion"},{"key":"2026062610402430000_16.2.e106082.56","unstructured":"NHS England . BI3 automated exchange transfusion for sickle cell care. London, 2015."},{"key":"2026062610402430000_16.2.e106082.57","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.transci.2017.05.020","article-title":"A 5-year cost analysis of automated red cell exchange transfusion for the management of recurrent painful crises in adult patients with sickle cell disease","volume":"56","author":"Tsitsikas","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"2026062610402430000_16.2.e106082.58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.10.350","article-title":"EE66 Estimated Cost of Automated Red Cell Exchange Transfusion (ARCET) for Treatment of Sickle Cell Disease (SCD) in the English NHS: Data From a Longitudinal Real-World Cohort","volume":"27","author":"Barcelos","year":"2024","journal-title":"Value Health"},{"key":"2026062610402430000_16.2.e106082.59","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/01.HS9.0000849672.40887.0f","article-title":"P1704: PROJECTED LIFETIME ECONOMIC BURDEN OF SEVERE SICKLE CELL DISEASE IN THE UNITED STATES","volume":"6","author":"Udeze","year":"2022","journal-title":"Hemasphere"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:41:03Z","timestamp":1782495663000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-106082"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106082","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}